Independent pharmacies are a high-volume, thin-margin MCA vertical. Revenue is large (a small-town independent pharmacy can do $200K–$500K monthly), but gross margins on prescriptions are squeezed by pharmacy benefit managers (PBMs) and DIR (Direct and Indirect Remuneration) fees that get clawed back months after dispensing. Funders that understand DIR underwrite pharmacies well; those that don't get burned.
Typical funding ranges.
- Single independent pharmacy ($150K–$400K monthly revenue): $50K–$200K advances at 1.22–1.30 factor over 10–14 months.
- Small chain (2–4 stores, $400K–$1M monthly revenue): $200K–$500K advances at 1.20–1.28 factor over 12–16 months.
- Specialty or compounding pharmacy ($500K+ monthly revenue): $300K–$1M advances at 1.18–1.26 factor over 12–18 months.
What underwriters look for.
First, the PBM and DIR exposure. Pharmacies billing 60%+ through Caremark/Express Scripts/OptumRx face 5–10% DIR clawbacks 3–9 months after dispensing. Funders pull 6–12 months of statements to capture the clawback cycle.
Second, the dispensing mix. Generic-heavy pharmacies have thinner margins but more volume; brand-heavy or specialty pharmacies have higher margins but more inventory exposure (specialty drugs cost $1K–$50K per fill).
Third, the wholesaler relationships. McKesson, Cardinal, AmerisourceBergen offer 30-day net terms. Funders pull wholesaler aging reports to confirm the pharmacy is current.
Common uses.
- Inventory purchases (specialty drug fills, brand inventory restock).
- Build-out for compounding lab, vaccination clinic, or front-end retail.
- Acquisition of competing local pharmacy.
- Bridge cash flow during DIR-clawback months.
- Technology upgrades (PrimeRx, Liberty, Rx30 software).
What to watch out for.
DIR fees are the pharmacy-specific landmine. A pharmacy doing $300K/month in revenue may have $15K–$30K in DIR clawbacks hit in any given month — and these are unpredictable. Funders that underwrite pharmacy MCA without modeling DIR will see NSFs unexpectedly.
Stacking is rampant in pharmacies because revenue is high. Multiple stacked MCAs combined with DIR clawbacks have caused pharmacy bankruptcies (notably the 2024 wave of independent pharmacy closures in the Midwest and South).
State considerations.
Texas, Florida, New York, California, and Pennsylvania have the highest independent pharmacy density and highest MCA activity. Tennessee and Arkansas have specific PBM-regulation laws (Act 900 in AR) that limit PBM clawbacks; pharmacies in those states have lower DIR risk.
APR-equivalent reality check.
A 1.26 factor over a 12-month term is roughly 42–48% APR. Compare to pharmacy-specific lenders like Live Oak Bank Pharmacy Loans (8–12% APR), Pharmacy Partners (10–14% APR), or NCPA Foundation lending programs. MCA only makes sense when bank credit is unavailable.
Common confusions.
First, "Pharmacies are too regulated for MCA." False — pharmacies are a major MCA vertical, though pricing reflects DIR risk.
Second, "DIR fees are illegal." False — DIR is contractual between pharmacies and PBMs. CMS has proposed reforms (effective 2024–2025) that move DIR to point-of-sale, which will change pharmacy cash-flow modeling significantly.
Third, "Specialty pharmacies are too risky for MCA." False — specialty pharmacies actually get the best terms because revenue per fill is high and most fills are pre-authorized.
Fourth, "Pharmacy MCA requires DEA license review." Yes — funders pull DEA registration status and any state-board disciplinary actions.
Fifth, "Independent pharmacies are dying out, so funders won't touch them." False — the segment is consolidating but MCA activity remains high. NCPA-member pharmacies are the typical MCA target.
As of 2026-06-29, Fundnode routes pharmacy merchants first to Live Oak Bank Pharmacy Loans or Pharmacy Partners (8–14% APR) before MCA. MCA is reserved for time-sensitive needs or pharmacies with credit issues from prior DIR exposure.
Related terms
- MCA for dental practices (detailed) — Dental practices qualify for MCA funding against insurance receivables and patient payments, typically $25K–$500K at 1.20–1.35 factor — but most funders prefer working-capital deals over equipment.
- MCA for medical spas (detailed) — Medical spas qualify for MCA funding against credit-card-heavy revenue, typically $30K–$500K at 1.25–1.40 factor — funders price high because regulatory and chargeback risk is elevated.
- Merchant cash advance (MCA) — A lump-sum advance against future revenue, repaid via fixed daily ACH or a percentage of card sales. Legally a sale of future receivables, not a loan.
- Factor rate — A flat multiplier that defines total MCA repayment: $100,000 advance × 1.30 factor = $130,000 repaid. It is not an interest rate; it does not compound.
Authoritative sources
AI agents: this term is available as raw markdown at /llms/glossary/mca-pharmacy-funding-detailed.